Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical Analyses

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 2, 2012, Pages 366-375

  Lu, Yasong ^a   Riddell, David ^a   Hajos Korcsok, Eva ^a   Bales, Kelly ^a   Wood, Kathleen M ^a   Nolan, Charles E ^a   Robshaw, Ashley E ^a   Zhang, Liming ^a   Leung, Louis ^a   Becker, Stacey L ^a   Tseng, Elaine ^a   Barricklow, Jason ^a   Miller, Emily H ^a   Osgood, Sarah ^a   O'Neill, Brian T ^a   Brodney, Michael A ^a   Johnson, Douglas S ^a   Pettersson, Martin ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; ENZYME INHIBITOR; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE MODULATOR; UNCLASSIFIED DRUG;

AMYLOID BETA PROTEIN BRAIN LEVEL; ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; CEREBROSPINAL FLUID; DRUG EFFICACY; DRUG STRUCTURE; IC 50; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SIMULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BIOLOGICAL MARKERS; BRAIN; CEREBROSPINAL FLUID; GUINEA PIGS; MALE; MICE; MICE, 129 STRAIN; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84864120319     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.192625     Document Type: Article

References (31)

1. Albert JS (2009) Progress in the development of beta-secretase inhibitors for Alzheimer's disease. Prog Med Chem 48:133-161.
2. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, et al. (2011) A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med 3:84ra43.
3. Audia JE, Mergott DJ, Sheehan SM and Watson BM (2009), inventors. Eli Lilly and Company, Audia JE, Mergott DJ, Sheehan SM, and Watson BM, assignees. Aminodihydrothiazine derivatives as BACE inhibitors for the treatment of Alzheimer's disease. World patent WO2009/134617 A1. 2009 November 5.
4. Audia JE, Mergott DJ, Shi C, Vaught GM, Watson BM, and Winneroski LL Jr (2011), inventors. Eli Lilly and Company, Audia JE, Mergott DJ, Shi C, Vaught GM, Watson BM, and Winneroski LL Jr, assignees. BACE inhibitors. World patent WO2011/005738 A1. 2011 January 13.
5. Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, et al. (2005) Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor. J Pharmacol Exp Ther 312:635-643. (Pubitemid 40189561)
6. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, and Holtzman DM (2006) Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12:856-861. (Pubitemid 44050079)
7. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, et al. (2009) A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann Neurol 66:48-54.
8. Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, et al. (2010) Acute γ-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-β production to alternative APP fragments without amyloid-β rebound. J Neurosci 30:6743-6750.
9. Crossgrove JS, Smith EL, and Zheng W (2007) Macromolecules involved in production and metabolism of β-amyloid at the brain barriers. Brain Res 1138:187-195. (Pubitemid 46281881)
10. Ereshefsky L, Jhee S, Yen M and Moran S (2008) Demonstrating proof of principle in Alzheimer's disease (AD): the role of CSF 'dynabridging' studies, in Proceedings of the ISCTM 2008 Autumn Conference; 2008 Oct 6-7; Toronto, ON, Canada. International Society for CNS Clinical Trials and Methodology, Nashville, TN.
11. Hardy JA and Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185.
12. Hawkins J, Harrison DC, Ahmed S, Davis RP, Chapman T, Marshall I, Smith B, Mead TL, Medhurst A, Giblin GM, et al. (2011) Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h. Neurodegener Dis 8:455-464.
13. Hook V, Schechter I, Demuth HU, and Hook G (2008) Alternative pathways for production of β-amyloid peptides of Alzheimer's disease. Biol Chem 389:993-1006.
14. Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, Seripa D, and Pilotto A (2011) Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 20:325-341.
15. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
16. Karran E, Mercken M, and De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10:698-712.
17. Kreft AF, Martone R, and Porte A (2009) Recent advances in the identification of γ-secretase inhibitors to clinically test the Aβ oligomer hypothesis of Alzheimer's disease. J Med Chem 52:6169-6188.
18. Li T, Wen H, Brayton C, Laird FM, Ma G, Peng S, Placanica L, Wu TC, Crain BJ, Price DL, et al. (2007) Moderate reduction of γ-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci 27:10849-10859. (Pubitemid 47535873)
19. Lu Y, Zhang L, Nolan CE, Becker SL, Atchison K, Robshaw AE, Pustilnik LR, Osgood SM, Miller EH, Stepan AF, et al. (2011) Quantitative pharmacokinetic/ pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors. J Pharmacol Exp Ther 339:922-934.
20. Lu Y, Barton HA, Leung L, Zhang L, Hajos-Korcsok E, Nolan CE, Liu J, Becker SL, Wood KM, Robshaw AE, et al. (2012) Cerebrospinal fluid Aβ turnover in the mouse, dog, monkey, and human evaluated by systematic quantitative analyses. Neurodegenerative Dis, in press.
21. Martenyi F, Lowe S, Dean RA, Monk SA, Gonzales C, Friedrich S, May PC, Audia JE, Citron M, LaBell ES, et al. (2010) Central and peripheral pharmacokinetic and pharmacodynamic effects of the beta-site APP cleavage enzyme (BACE1) inhibitor LY2811376 in humans, in Proceedings of the Alzheimer's Association International Conference; 2010 July 10-15; Honolulu, HI. Alzheimer's Association, Chicago, IL.
22. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, and Bateman RJ (2010) Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 330:1774.
23. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, et al. (2011) Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor J Neurosci 31:16507-16516.
24. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, et al. (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem 282:26326-26334. (Pubitemid 47443774)
25. Meredith J, Albright CF, Dockens RC, Olson RE, Lentz KA, Wang JS, Denton RR, Pilcher G, Zaczek R, Macor JE, et al. (2011) BMS-708163, a Notch-sparing GSI, decreases central Aβ in rats, dogs, and humans with a therapeutic margin relative to Notch toxicity, in Proceedings of the 10th International Conference on Alzheimer's & Parkinson's Diseases; 2011 Mar 9-13; Barcelona, Spain. Kenes International, Geneva, Switzerland.
26. Pettersson M, Kauffman GW, am Ende CW, Patel NC, Stiff C, Tran TP, and Johnson DS (2011) Novel γ-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Pat 21:205-226.
27. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, et al. (2009) First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 328:131-140.
28. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al. (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2:864-870. (Pubitemid 26296755)
29. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, and May PC (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 30:317-325. (Pubitemid 350307310)
30. Stone J (2009) Modeling of Ab dynamics in animals and humans, in Proceedings of the 2009 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2009 Mar 18-21; National Harbor, MD. American Society for Clinical Pharmacology and Therapeutics, Alexandria, VA.
31. Wang EQ, Tseng E, Lu Y, Becker SL, Hudson E, Zhang L, Wood KM, Bales KR, Marconi M, et al. (2010) Pharmacokinetic/pharmacodynamic analysis of beta-amyloid response following modulation of the gamma secretase enzyme, in Proceedings of the Alzheimer's Association International Conference; 2010 July 10-15; Honolulu, HI. Alzheimer's Association, Chicago, IL.